A Phase II Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2015
At a glance
- Drugs Mocetinostat (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 28 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 08 Dec 2010 Status changed from suspended to completed.
- 07 Dec 2010 Results will be reported at ASH 2010, according to a MethylGene media release.